by Sean Hutchinson | Jan 25, 2024 | EPO
When the EPO’s Enlarged Board of Appeal issued its decision in G 2/21 (the “plausibility” referral), many were left wondering what the requirements were for a patent applicant/proprietor to be able to rely on post-filed evidence in support of inventive step. However,...
by David Eyre | Jan 22, 2024 | US & International
Background – Skinny Labelling Enacted by the Hatch–Waxman Act In 1984, the US Congress introduced a law called the Drug Price Competition and Patent Term Restoration Act, or the “Hatch–Waxman” Act after the two sponsors of the bill: Representative Henry Waxman and...
by Vicky Colley | Jan 18, 2024 | News
But, let it be known that Schlich is a company full of dedicated, persistent and mildly competitive employees! 2023 was a year for renovation in our offices; in July we opened our second Littlehampton office and at the end of the year a treadmill desk for each office...
by Alyson Lam | Jan 12, 2024 | Trademarks
Prior attempts – Puck Schrover case Previously, several models have filed applications to register trade marks of real-life pictures but have mostly been unsuccessful. One of the recent cases involved the figurative mark of Dutch model Puck Schrover. The application...
by Vicky Colley | Jan 8, 2024 | News
Schlich is one of just 25 firms to be recommended. We have been chosen for our work in the Pharma and Biotechnology, Medical Technology fields of expertise, as well as our work in EPO Oppositions. In the ranking, company founder, George Schlich, was picked out as a...
Recent Comments